Point of Care Diagnostics Market

Point of Care Diagnostics Market

  • Lowest Price Guaranteed From USD 4,899

  • Companies Covered
    424

  • Pages
    274

  • View Count
    13620

Point of Care Diagnostics Market Overview

The point of care diagnostics market for infectious diseases is estimated to be worth $1,986 million in 2025 and is expected to grow at CAGR of 13% during the forecast period. According to the World Health Organization (WHO), the big three infectious diseases, namely human immunodeficiency virus / acquired immunodeficiency syndrome (HIV / AIDS), malaria and tuberculosis (TB), are reported to be the cause of approximately 2.5 million annual fatalities worldwide.

Moreover, the pathogens responsible for causing these diseases are known to undergo selective mutations, which make them resistant to commonly used antibiotics. This impedes the effective treatment of the aforementioned clinical conditions. Since the pathophysiology of such diseases is known to evolve with time, better diagnostic tools with high sensitivity and specificity are required for timely diagnosis and better treatment related decision-making. For diseases of bacterial origin, diagnosis is based on culturing the pathogen; this is considered the current gold standard. Although these methods are highly specific, they are time consuming, requiring three to five days for detecting the responsible pathogen. On the other hand, in case of viral infections, molecular diagnostic platforms, such as next generation sequencing and real-time polymerase chain reactions, are typically used. However, these molecular level analytical techniques are expensive, complicated, and generally inaccessible in resource-limited settings. 

Given the aforementioned challenges, the medical industry is consistently engaged in efforts to innovate in assay formats, developing better biosensors, and bioanalytical platforms to expedite the diagnosis process. The concept of point of care testing, or rapid diagnostics, has become even more popular with the novel coronavirus outbreak. Unlike the traditional laboratory-based tests, the results of a point of care testing can be made available instantaneously (as fast as 5 minutes). This facilitates faster diagnosis and prompt decision making with respect to treatment, thereby, enabling the containment of infectious diseases at an early stage of transmission and preventing outbreaks. Additionally, point of care device reduces the reliance on presumptive treatment, thereby, helping curb the inappropriate use of antibiotics. Till date, point of care testing are widely used for the diagnosis of diseases, such as chikungunya, COVID-19, dengue, hepatitis, malaria, pneumonia, and tuberculosis. In future, we expect such tests / assays to dominate the poc market.

This image highlights the context of Point of Care Diagnostics for Infectious Diseases Market report. Over time, innovation in bioanalytical techniques, biosensors, and the introduction of lab-on-a-chip technologies, have enabled the development of versatile point-of-care diagnostics, which facilitate better disease diagnosis, monitoring, and management This image presents current market landscape of Point of Care Diagnostics. Nearly 1,600 point-of-care diagnostic solutions for infectious disorders are at various stages of development; in fact, the portfolio of several developers includes point-of-care tests for the diagnosis of multiple indications This image provides list of Point of Care Diagnostics. Amidst other initiatives, companies have recently demonstrated a focused approach towards the development of point-of-care diagnostics for novel coronavirus (SARS-CoV-2 strain)

Recent Developments in Point of Care Diagnostics Market

Several recent developments have taken place in the field of point of care diagnostics market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In May 2023, Molbio Diagnostics entered into a collaboration with ShanMukha to design, develop and commercialize point of care device to diagnose hemoglobin-related diseases. 
  • In August 2023, CrisprBits in collaboration with MolBio Diagnostics launched point-of-care CRISPR-based tests.

Scope of the Point of Care Diagnostics Market Report

The ‘Point of Care Diagnostics Market for Infectious Diseases, 2020-2025’ market report features an extensive study on current market landscape, market size, market share, market growth, market forecast, market outlook and future opportunities of the point of care diagnostics market. In addition, it features an elaborate discussion on the likely future opportunity associated with point of care devices during the forecast period.

This image provides list of Point of Care Diagnostics. The market for HIV/AIDS and hepatitis as well as respiratory infections features the presence of seasoned industry veterans and recent players, offering tests and devices for the diagnosis of target indications This image presents current market landscape of Point of Care Diagnostics for Infectious Diseases. A number of solutions are now available for the diagnosis of infectious diseases and are based on multiple types of analytes, depending on the type of clinical condition This image highlights the geographical distribution of Point of Care Diagnostic Developers. Majority of the stakeholders in this competitive market are small / mid-sized firms, offering a variety of products for the diagnosis of target disease indications

Amongst other elements, the market research report includes:

  • A detailed review of the overall landscape of point-of-care diagnostics for COVID-19, providing information on current development status of point-of-care diagnostics (under development, research use only, and available), type of product (test and point of care device / platform), type of technology (fluorescence immunoassay, lateral flow, molecular diagnostics, solid phase, vertical flow, and others), type of sample (blood, nasal / nasopharyngeal secretions, sputum, urine, and others), sensitivity range (<90%, 90-95%, and >95%), specificity range (<90%, 90-95%, and >95%), and turnaround time (≤5 minutes, >5-15 minutes, >15-30 minutes, and >30 minutes). In addition, the report presents the details of the companies developing these point-of-care diagnostics, including information on year of establishment, company size and location of headquarters.
  • A detailed review of the overall landscape of Point-of-Care Diagnostics for tropical diseases, providing information on current development status of point-of-care diagnostics (under development, research use only, and available), type of product (test and point of care device / platform), type of technology (flow-through, fluorescence immunoassay, lateral flow, molecular diagnostics, solid phase, and others), target disease indication (chikungunya, dengue, Ebola, malaria, and zika), type of sample (blood, sputum, and urine), sensitivity range (<90%, 90-95%, and >95%), specificity range (<90%, 90-95%, and >95%), and turnaround time (≤5 minutes, >5-15 minutes, >15-30 minutes, and >30 minutes). In addition, the report presents the details of the companies developing these point-of-care diagnostics, including information on year of establishment, company size and location of headquarters.
  • A detailed review of the overall landscape of point-of-care diagnostics for respiratory infections, providing information on current development status of point-of-care diagnostics (under development, research use only, and available), type of product (test and point of care device / platform), type of technology (fluorescence immunoassay, lateral flow, molecular diagnostics, solid phase, and others), target disease indication (influenza, pneumonia, and tuberculosis), type of sample (blood, cerebrospinal fluid, nasal / nasopharyngeal secretions, sputum, urine, and others), sensitivity range (<90%, 90-95%, and >95%), specificity range (<90%, 90-95%, and >95%), and turnaround time (≤5 minutes, >5-15 minutes, >15-30 minutes, and >30 minutes). In addition, the report presents the details of the companies developing these point-of-care diagnostics, including information on year of establishment, company size and location of headquarters.
  • A detailed review of the overall landscape of point-of-care diagnostics for HIV/AIDS and hepatitis, providing information on current development status of point-of-care diagnostics (under development, research use only, and available), type of product (test and point of care device / platform), type of technology (flow-through, fluorescence immunoassay, lateral flow, molecular diagnostics, solid phase, vertical flow, and others), target disease indication (hepatitis A, hepatitis B, hepatitis C, and HIV/AIDS), type of sample (blood, feces, oral fluid, and urine), sensitivity range (<90%, 90-95%, and >95%), specificity range (<90%, 90-95%, and >95%), and turnaround time (≤5 minutes, >5-15 minutes, >15-30 minutes, and >30 minutes). In addition, the report presents the details of the companies developing these point-of-care diagnostics, including information on year of establishment, company size and location of headquarters.
  • A detailed study of the overall landscape of point-of-care diagnostics for infectious diseases, featuring analyses based on a number of relevant parameters, such as type of technology (flow-through, fluorescence immunoassay, lateral flow, molecular diagnostics, solid phase, vertical flow, and others), target disease indication (chikungunya, COVID-19, dengue, Ebola, hepatitis, HIV/AIDS, influenza, malaria, pneumonia, tuberculosis, and zika), sensitivity range (<90%, 90-95%, and >95%), specificity range (<90%, 90-95%, and >95%), and turnaround time (≤5 minutes, >5-15 minutes, >15-30 minutes, and >30 minutes).
  • An analysis of the partnerships that have been inked by stakeholders in point of care diagnostics market, during the period between January 2018 and July 2020, covering distribution and supply agreements, product development and commercialization agreements, commercialization agreements, mergers and acquisitions, product development and manufacturing agreements, research and development agreements, and product / technology integration agreements.
  • A detailed analysis on acquisition targets, taking into consideration the historical trend of the activity of the companies that have acquired other firms since 2018, and offering a means for other industry stakeholders to identify potential acquisition targets.

The key objective of point of care diagnostics market report is to provide a detailed market analysis in order to estimate the existing market size, market value, statistics and future opportunity for point of care diagnostics market or  poc market during the forecast period. Based on various parameters, such as number of available / under development products, average price of point-of-care tests and estimated annual adoption rates, we have provided an informed estimate on the likely evolution of the market over the forecast period 2020-2025. The market report also features the likely distribution of the current and forecasted opportunity across [A] target disease indications (chikungunya, COVID-19, dengue, Ebola, hepatitis, HIV/AIDS, influenza, malaria, pneumonia, tuberculosis, and zika), [B] type of technology (lateral flow, molecular diagnostics, fluorescence immunoassay, solid phase, and others), and [C] key geographical regions (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s growth.

This image highlights the partnership activity undertaken by players engaged in Point of Care Diagnostics Market. The rising interest in this field is reflected by the increase in partnership activity in the recent past, involving both international and indigenous stakeholders focused on distribution of POC tests / technologies This image describes the potential acquisition targets. In fact, an evaluation of 275+ stakeholders engaged in the development of POCDs for infectious diseases revealed the existence of several likely acquisition targets, across different geographical regions This image highlights the market segments of Point of Care Diagnostics Market for Infectious Diseases. The market is likely to grow at a CAGR of ~12%; the anticipated opportunity is expected to be distributed across various types of infectious diseases, type of technology and geographies

The opinions and insights presented in the market report were influenced by discussions held with senior stakeholders in the industry. The market research report features detailed transcripts of interviews held with the following industry stakeholders:

  • Reuven Duer, Founder and CEO, Proactive Diagnostics
  • Giffin Daughtridge, CEO, UrSure
  • Abhinav Thakur, Managing Director, Accurex Biomedical
  • Gerrit Van Roekel, Director of Business Development, Hemex Health
  • Sofiane Bennacer, Business Development Manager, Credo Diagnostics Biomedical

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What is point of care diagnostics?

Answer: Point of care diagnostics refers to the quick identification of analytes close to the patient, facilitating better disease diagnosis, monitoring, and management.

Question 2: How big is the point of care diagnostics market for infectious diseases?

Answer: The point of care diagnostics market size for infectious diseases is estimated to be worth $1,986 million in 2025.

Question 3: What is the projected market growth of the point of care diagnostics market for infectious diseases?

Answer: The point of care diagnostics market for infectious diseases is expected to grow at compounded annual growth rate (CAGR) of 13% during the forecast period 2020 – 2025.

Question 4: Who are the leading companies in the point of care diagnostics market for infectious diseases?

Answer: Examples of key companies engaged in point of care diagnostics market for infectious diseases (which have also been profiled in this market report; the complete list of companies is available in the full report) include Aduro Biotech, Bristol-Myers Squibb, Eisai, GlaxoSmithKline, ImmuneSensor Therapeutics, Merck, Noxopharm, Spring Bank Pharmaceuticals, Synlogic, Avammune Therapeutics, Curadev, ImmuneSensor Therapeutics, Nimbus Therapeutics, Sirenas, Spring Bank Pharmaceuticals, STINGINN and STipe Therapeutics.

Question 5: How many products are presently being evaluated by players engaged in the point of care diagnostics market for infectious diseases?

Answer: Presently, close to 1,600 products are being evaluated by players engaged in the point of care diagnostics market for infectious diseases.

Question 6: How many partnership deals have been inked by stakeholders engaged in the point of care diagnostics market for infectious diseases?

Answer: Since 2018, more than 105 partnership deals have been inked by stakeholders engaged in the point of care diagnostics market for infectious diseases.

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com